Efforts to ensure safety of hospital pharmacy personnel occupationally exposed to antineoplastic drugs during a preparation task

Hospital Pharmacy

Volumn 42, Issue 3, 2007, Pages 209-218

  Ikeda, Kenji ^a   Yagi, Yuriko ^b   Takegami, Manabu ^b   Lu, Yuquan ^b   Morimoto, Kanehisa ^c   Kurokawa, Nobuo ^c  

^a OSAKA OHTANI UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anthracycline; Antineoplastic agents; Chemotherapy; Environment; Exposure; Occupational; Prepare

Indexed keywords

ACETONITRILE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FORMIC ACID; METHANOL; METHOTREXATE;

ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG URINE LEVEL; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PHARMACY; HUMAN; LIQUID CHROMATOGRAPHY; OCCUPATIONAL EXPOSURE; PERIPHERAL LYMPHOCYTE; PHARMACIST; SISTER CHROMATID EXCHANGE; SOLID PHASE EXTRACTION; WORKLOAD;

EID: 34247353321     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4203-209     Document Type: Article

References (36)

1. NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Available at: http://www.cdc.gov/niosh/docs/2004-165/. Accessed February 9, 2007.
2. Antineoplastic Agents. Occupational hazards in hospitals. Available at: http://www.cdc.gov/niosh/docs/2004-102/. Accessed February 9, 2007.
3. Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003;76:5-10.
4. Evelo CT, Bos RP, Peters JG, Henderson PT. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986;58:151-155.
5. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt H, Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994;51:229-233.
6. Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health. 1997;70:209-214.
7. Ensslin AS, Pethran A, Schierl R, Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994;65:339-342.
8. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997;70:205-208.
9. Sessink PJ, Cerná M, Rössner P, et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994;309:193-199.
10. Hessel H, Radon K, Pethran A, et al. The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs - evaluation by the micronucleus assay. Mutat Res. 2001;497:101-109.
11. Pilger A, Köhler I, Stettner H, et al. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs. Int Arch Occup Environ Health. 2000;73:442-448.
12. Sottani C, Tranfo G, Bettinelli M, Faranda P, Spagnoli M, Minoia C. Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel. Rapid Commun Mass Spectrom. 2004;18:2426-2436.
13. Vouillamoz-Lorenz S, Bauer J, Lejeune F, Decosterd LA. Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. J Pharm Biomed Anal. 2001;25:465-475.
14. Storme T, Mercier L, Deroussent A, et al. Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;820:251-259.
15. Sabatini L, Barbieri A, Tosi M, Violante FS. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom. 2005;40:669-674.
16. Castiglia L, Miraglia N, Pieri M, et al. Mono- and diiodocyclophosphamide as possible internal standards for cyclophosphamide quantification: characterization by ion trap multi-stage mass spectrometry and effects of iodine-chlorine substitution on the fragmentation pattern. Rapid Commun Mass Spectrom. 2005;19:1858-1866.
17. Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U. Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18:1472-1478.
18. Sadagopan N, Cohen L, Roberts B, Collard W, Omer C. Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. J Chromatogr B Biomed Sci Appl. 2001;759:277-284.
19. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl. 2000;748:383-388.
20. Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 1997; 691:95-104.
21. Lartigue-Mattei C, Chabard JL, Touzet C, Bargnoux H, Petit J, Berger JA. Plasma cyclophosphamide assay by selective ion monitoring. J Chromatogr. 1984;310:407-411.
22. Ikeda K, Takegami M, Tajima S, et al. Upgrading a pharmaceutical information system for preparation of parenteral admixture for ambulant chemotherapy in a hospital pharmacy using end-user prototype model, and comprehensive evaluation of upgraded system. Jpn J Pharm Health Care Sci. 2006;32:436-444.
23. Lachâtre F, Marquet P, Ragot S, Gaulier JM, Cardot P, Dupuy JL. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;738:281-291.
24. Nicholls G, Clark BJ, Brown JE. Solid-phase extraction and optimized separation of doxorubicin, epirubicin and their metabolites using reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal. 1992;10:949-957.
25. Camaggi CM, Comparsi R, Strocchi E, Testoni E, Pannuti F. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol. 1988;21:216-220.
26. Fogli S, Danesi R, Innocenti F, et al. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit. 1999;21:367-375.
27. Li R, Huang J. Chromatographic behavior of epirubicin and its analogues on high-purity silica in hydrophilic interaction chromatography. J Chromatogr A. 2004;1041:163-169.
28. Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and mini-bags. J Clin Pharm Ther. 1990;15:279-289.
29. Thomas AH, Quinlan GJ, Gutteridge JM. Assay of doxorubicin and 4′-epidoxorubicin by reversed-phase ion-pair chromatography. J Chromatogr. 1984;299:489-494.
30. Blaszkowska J, Bratkowska W, Lopaczynska D, Strozynski H, Ferenc T. Chromosome aberrations, sister chromatid exchanges (SCE) and cell division kinetics in human lymphocytes exposed in vitro to purified trypsin inhibitor from Ascaris. J Appl Genet. 2004;45:265-274.
31. Khalil AM, Qassem W. Cytogenetic effects of pulsing electromagnetic field on human lymphocytes in vitro: chromosome aberrations, sister-chromatid exchanges and cell kinetics. Mutat Res. 1991;247:141-146.
32. Khalil AM, Maslat AO. Chromosome aberrations, sister-chromatid exchanges and cell-cycle kinetics in human peripheral blood lymphocytes exposed to organoselenium in vitro. Mutat Res. 1990;232:227-232.
33. Lu Y, Morimoto K, Takeshita T, Takeuchi T, Saito T. Genotoxic effects of alpha-endosulfan and beta-endosulfan on human HepG2 cells. Environ Health Perspect. 2000;108:559-561.
34. Gollapudi B, Kamra OP. Application of a simple giemsa-staining method in the micronucleus test. Mutat Res. 1979;64:45-46.
35. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol. 1988;21:221-228.
36. El-Mahdy Sayed Othman O. Cytogenetic effect of the anticancer drug epirubicin on Chinese hamster cell line in vitro. Mutat Res. 2000;468:109-115.